Lyell Immunopharma (LYEL) Interest & Investment Income (2020 - 2026)

Lyell Immunopharma's Interest & Investment Income history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 43.19% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $11.4 million (down 45.94% YoY), while the FY2025 annual figure was $13.1 million, down 45.65% from the prior year.
• Interest & Investment Income came in at $2.2 million for Q1 2026 at Lyell Immunopharma, down from $2.7 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $7.1 million in Q4 2023 to a low of $397000.0 in Q1 2022.
• A 5-year average of $4.1 million and a median of $3.9 million in 2025 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income soared 1032.75% in 2023 and sank 48.52% in 2025, its largest moves.
• Lyell Immunopharma's Interest & Investment Income stood at $3.5 million in 2022, then jumped by 105.15% to $7.1 million in 2023, then slumped by 30.55% to $4.9 million in 2024, then plunged by 45.61% to $2.7 million in 2025, then declined by 18.01% to $2.2 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $2.2 million, $2.7 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison